Clinical Data, Inc. is a biotechnology company with a focuses on the development of therapeutics. Its late stage compounds include vilazodone, a potential first-in-class drug candidate for the treatment of depression, and apadenoson, which is trademarked under the name Stedivaze a potential best-in-class vasodilator for use in myocardial perfusion imaging. On August 4, 2008, the Company acquired the assets of Adenosine Therapeutics, LLC, a developer of drug products based on its extensive portfolio of composition of matter and method of use patents relating to selective adenosine receptor modulators, including Stedivaze. On October 27, 2008, the Company entered into a definitive merger agreement to acquire Avalon.